Pseudorotaxanes, rotaxanes and catenanes formed by metal ions templating
US-2015051393-A1 · Feb 19, 2015 · US
US11045561B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11045561-B2 |
| Application number | US-201815939261-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 28, 2018 |
| Priority date | Mar 28, 2017 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a novel method for synthesizing hyperpolarized xenon-129 (HP Xe) biosensors by using pseudo-rotaxane structures of gamma-cyclodextrin. These supramolecular complexes form novel ternary structures in the presence of HP Xe which can be detected via 129 Xe MR spectroscopy and imaging techniques. The rotaxane-type complex can be tagged with an affinity label for detecting a target in a biological subject.
Opening claim text (preview).
What is claimed is: 1. A supramolecular complex useful as a biosensor, comprising: (a) a macrocycle host defining a hydrophobic cavity; (b) an axle comprising a molecular chain functionalized with an affinity tag for a target inside a biological subject, wherein the affinity tag is at one or both ends of the molecular chain, and wherein the axle is threaded through the macrocycle cavity; and (c) a xenon atom, wherein the cavity of the macrocycle host is large enough to accommodate and reversibly encapsulate both a cross section of the axle and the xenon atom at the same time. 2. The supramolecular complex of claim 1 , wherein the macrocycle host is water-soluble. 3. The supramolecular complex of claim 1 , wherein the xenon atom is dissolved in a solution. 4. The supramolecular complex of claim 1 , wherein the macrocycle host defines a cavity that is larger than about 6.5 Å in inner diameter. 5. The supramolecular complex of claim 1 , wherein the macrocycle host is a cyclodextrin. 6. The supramolecular complex of claim 5 , wherein the macrocycle host is a γ-cyclodextrin. 7. The supramolecular complex of claim 1 , wherein the axle comprises an alkyl chain. 8. The supramolecular complex of claim 7 , wherein the axle has at least five carbons in its backbone. 9. The supramolecular complex of claim 1 , wherein the axle is capped with a hydrophobic end group at each of its two ends, at least one of the end groups being or comprising the affinity tag. 10. The supramolecular complex of claim 1 , wherein the affinity tag comprises a ligand selected for its affinity for a biological target inside a subject. 11. The supramolecular complex of claim 1 , wherein the affinity tag comprises a detectable label. 12. The supramolecular complex of claim 11 , wherein the affinity tag comprises a fluorophore. 13. The supramolecular complex of claim 1 , wherein the affinity tag comprises thioflavin T. 14. The supramolecular complex of claim 1 , detectable by xenon-based magnetic resonance imaging or spectroscopy. 15. A biosensor comprising: (a) a cyclodextrin molecule defining a cavity; (b) an alkyl chain molecule functionalized with an affinity tag at one or each of its two ends, wherein the affinity tag has an affinity for a target inside a biological subject, and wherein the alkyl chain molecule is threaded through the cavity in the cyclodextrin; and (c) a xenon atom in the cavity of the cyclodextrin. 16. The biosensor of claim 15 , wherein the affinity tag comprises a detectable label. 17. The biosensor of claim 15 , wherein the affinity tag is part of an end group that also serves as a stopper to prevent de-threading. 18. The biosensor of claim 17 , wherein the end group is hydrophobic. 19. The biosensor of claim 17 , wherein the end group comprises an ethylimidazolium group or an anthracene group. 20. The biosensor of claim 15 , wherein the xenon atom is xenon-129.
Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes · CPC title
Compositions of unspecified macromolecular compounds · CPC title
Polyrotaxanes; Polycatenanes · CPC title
with fluorescent label · CPC title
involving the use of a carrier gas for transport to the sensor · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.